Abstract
Ten-Year Response to Crizotinib in ALK-positive Inflammatory Myofibroblastic Tumors: Case Reports
Full Text
Sign-in/Register to access full text options
Published version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have